This event has ended

Multi-party Alliances in the Biomedical Industry: New Discovery and Development Models

ASAP Silicon Valley/NorCal

Multi-party Alliances in the Biomedical Industry: New...

Ticket Information

No tickets available.

Share Multi-party Alliances in the Biomedical Industry: New Discovery and Development Models

Event Details

This event has been rescheduled for Fall 2011. Please watch our newsletter for details.

 

 

As the need for innovative and cost effective therapies intensifies around the globe, the biomedical products industry is exploring new models of drug discovery and development. Along with traditional partnerships, these "new models" are increasingly based on the formation of multi-party alliances between non-profit organizations, universities, philanthropic foundations and biopharmaceutical companies, working together to discover, develop and commercialize new therapies.

Due to the structure and nature of the organizations involved in such new collaborations, the establishment and management of strategic alliances may often be a formidable challenge.

Join us for a highly interactive and educational evening in which we explore the key challenges and best practices in a successful multi-party alliance to create artemisinin, a semi-synthetic component used to make anti-malarial treatments.  The alliance, led by the Institute for OneWorld Health (iOWH), included the University of California at Berkeley, Amyris, and Sanofi Aventis.

In addition, our panel of experts from Bayer Healthcare, Monogram Biosciences and Medivation will compare and contrast various types of alliances, and highlight the critical success factors and pitfalls inherent to alternative partnering arrangements.
 
Attendees of this event will learn:

  • How to proactively manage multiple relationships with various types of partners:  academic, philanthropy, large and small private companies
  • How to work in synergy between the Business Development, Alliances Management and Project Management functions to ensure successful partnerships
  • How to identify critical success factors in your situation while avoiding the common pitfalls of strategic partnering 
  • How to establish and formalize Alliances Management capabilities as a way to become the “partner of choice” in your sector

When
June 7, 2011
5:30 - 6:45 p.m. Networking, Happy Hour
6:45 - 8:30 p.m. Panel & Discussion

Location
University of California-San Francisco
Medical Center at Mission Bay
Genentech Hall, 600 16th St.,  Room N-114
San Francisco, CA 94158

Cost

ASAP-SV is offering special pricing for this academic event hosted at UCSF

Early Bird through June 1:

Member $15
UCSF Students and Faculty $15
Partners $15
Non-member $25
 

Advanced registration through June 6, 3pm:

Member $20
UCSF Students and Faculty $20
Partners $20
Non-member $30

Onsite:

Member $25
UCSF Students and Faculty $25
Partners $25
Non-member $35

 

About Our Panel

Peter G. Nell, PhD
Director Business Development & Alliance Management
Bayer HealthCare Pharmaceuticals

Peter Nell recently moved to Bayer's new research site in Mission Bay, San Francisco to support the U.S. Science Hub in expanding Bayer’s research collaborations with U.S. academic institutions and biotech companies. He brings in experience in licensing and alliance management as well as profound knowledge in the drug discovery process. Currently, he is also the alliance manager of Bayer's collaboration with OncoMed Pharmaceuticals to develop anti-cancer stem cell therapeutics. Prior to his current position, Peter Nell worked at the Bayer Schering Pharma headquarters in Berlin, Germany within the Global Business Development & Licensing group being responsible for in-licensing of all target discovery projects and women’s healthcare projects up to including Phase I. This followed a position as assistant to the Head of Global Therapeutic Research building up an intensive network and gaining a thorough insight into the complete drug discovery process. He started with Bayer as a lab head in medicinal chemistry with a focus on cardiovascular drug discovery projects at the Bayer AG research site in Wuppertal, Germany. Peter Nell completed a postdoctoral fellowship at Stanford University as an Alexander von Humboldt stipend. He received his doctorate in Organic Chemistry from the University of Marburg, Germany after studies of Chemistry at the Universities of Heidelberg, Bristol, U.K., and Freiburg.  

Ken Hitchner, M.A.,
Vice President of Pharmaceutical Collaborations
Monogram Biosciences

Ken joined Monogram as Director of Project Management in May 1999 and was named Vice President of Pharmaceutical Collaborations in October 2003. Prior to Monogram, Ken was the Director of Project Management at Gilead Sciences. Ken was with Genentech for 15 years where he held a number of positions in Product Development and Quality Control. Ken received his bachelor's degree in zoology from DePauw University and a master's degree in biology from San Francisco State University.

Patrice Bruneman, MBA, CA-AM
Director, Strategic Alliances
Medivation

Ms. Bruneman graduated with a Bachelor of Science degree in Zoology from the University of WI –Madison, where she started her career in academic research studying diabetic retinopathy.  After moving to the Bay Area, Ms. Bruneman continued to work in bench science at various companies including Chiron, where she worked on pipeline discovery projects for cancer therapies.  Ms. Bruneman entered the Pharmaceutical industry as a project manager with Elan Pharmaceuticals through their commercial launch for the products Zonegran and Myobloc.  She continued project management at Theravance, submitting several INDs for anti-infective, asthma and IBS drug candidates.  After obtaining her MBA at San Francisco State University, Patrice wanted to focus her drug development career in areas of unmet medical needs so she joined Novacea Inc, where she worked on two programs in NHL and Prostate cancer.   After the failure of Novacea’s Phase 3 prostate cancer trial, Patrice applied to Medivation as a Project Manager for their Alzheimer’s disease program. A better alternative arose and she signed on as Medivation’s Alliance Manager to oversee the collaboration with Pfizer and subsequently the collaboration with Astellas for the prostate cancer drug.  Both programs at Medivation are in Phase 3 development.

Julie Cheng, Esq.
Former General Counsel & Vice President Business Development
Institute for OneWorld Health (iOWH). 

During her tenure at iOWH, Ms. Cheng oversaw all of iOWH’s legal matters and was responsible for business development including setting up key partnerships among iOWH, academia and pharmaceutical companies in different disease areas.  Her legal experience has primarily been in the corporate world, including working at the FMC Corporation and Alcon Laboratories Inc.  Prior to joining iOWH, she spent almost seven years with Bayer HealthCare, with her most recent position being Assistant General Counsel. Before that she worked in Philadelphia for Rohm and Haas Company, where her focus was on international intellectual property.  Julie’s community activities have included participating on the board of the Public Interest Law Center of Philadelphia (PILCOP) and working with Big Brothers Big Sisters, Philadelphia Volunteer Lawyers for the Arts, the West Texas Legal Services, and the AIDS Outreach Center.  Julie has been involved with the National Asian Pacific American Bar Association (NAPABA) as well as local Asian Pacific American bar associations for several years.  Julie was also a member of the ABA Special Committee on Bioethics and the Law from 2001 – 2004.  Julie received her B.A. from Reed College and her J.D. from Franklin Pierce Law Center.

Nina Grove, M.A., M.P.H
Principal at N. Grove Consulting

Nina provides biopharmaceutical and global health expertise to both public and private sector clients.  Previously, Ms Grove was Vice President, Commercial Planning and Strategy at the Institute for OneWorld Health where she focused on strategic collaborations, access/delivery strategies, and leadership of public-private partnerships, including the malaria program.  Ms. Grove has over 25 years of biopharmaceutical product development experience in all aspects of drug development.   At Genentech, Inc., Nina held positions in Quality Control, Product Operations, Product Development, and as Director of Commercial Regulatory Affairs where she was responsible for the product launch of four new drugs for asthma, cancer, and psoriasis. In addition to team leadership and project management roles for international drug and vaccine development and information technology implementations, she also served on several key committees and established a program management office.  Prior to joining Genentech, Nina performed laboratory research both at the University of California, Berkeley, and at Stanford University. Nina earned her BA in Biology from the University of California at Santa Cruz and Masters degrees in Medical Microbiology and Public Health from the University of California, Berkeley. 

Have questions about Multi-party Alliances in the Biomedical Industry: New Discovery and Development Models? Contact ASAP Silicon Valley/NorCal

Where


University of California-San Francisco
Medical Center at Mission Bay
Genentech Hall, 600 16th St., Room N-114
, San Francisco, CA 94158


Organizer

ASAP Silicon Valley/NorCal

We are a dynamic chapter of ASAP that focuses on addressing the alliance-related needs of companies in the Northern California and Bay Area.

We offer our members a wide variety of targeted events and programs, current information on industry best practices, case studies and education to support and grow your business and professional skills.

  Contact the Organizer

Please log in or sign up

In order to purchase these tickets in installments, you'll need an Eventbrite account. Log in or sign up for a free account to continue.